These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27685149)

  • 1. Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules.
    Kampers J; Orjuela-Grimm M; Schober T; Schulz TF; Stiefel M; Klein C; Körholz D; Mauz-Körholz C; Kreipe H; Beier R; Maecker-Kolhoff B
    Leuk Lymphoma; 2017 Mar; 58(3):633-638. PubMed ID: 27685149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.
    Twist CJ; Hiniker SM; Gratzinger D; Gutkin PM; Merriott DJ; Iagaru A; Link MP; Donaldson SS
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27803. PubMed ID: 31062898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
    Ranganathan S; Webber S; Ahuja S; Jaffe R
    Pediatr Dev Pathol; 2004; 7(4):348-60. PubMed ID: 14564542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically.
    Pitman SD; Huang Q; Zuppan CW; Rowsell EH; Cao JD; Berdeja JG; Weiss LM; Wang J
    Am J Surg Pathol; 2006 Apr; 30(4):470-6. PubMed ID: 16625093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review.
    Zhou K; Gong D; Han Y; Huang W
    Ann Hematol; 2024 Jul; 103(7):2207-2213. PubMed ID: 37749317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report.
    Gunes AK; Demir I; Pehlivan M
    J Oncol Pharm Pract; 2021 Mar; 27(2):509-512. PubMed ID: 32762294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD30 expression and survival in posttransplant lymphoproliferative disorders.
    Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
    Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of paediatric monomorphic post-transplant lymphoproliferative disorders with low-intensity treatment: A multicentre international experience.
    Guerra-García P; Bomken S; Ling R; Lazareva A; Gupte G; Amrolia P; Andrés M; Diez-Sebastián J; Taj MM
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31053. PubMed ID: 38757407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of post-transplant lymphoproliferative disease presenting as CD20-expressing, Epstein-Barr-virus positive Hodgkin lymphoma.
    Stern M; Herrmann R; Rochlitz C; Dirnhofer S; Pless M
    Eur J Haematol; 2005 Mar; 74(3):267-70. PubMed ID: 15693799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.
    Rosenberg AS; Klein AK; Ruthazer R; Evens AM
    Am J Hematol; 2016 Jun; 91(6):560-5. PubMed ID: 26928381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease.
    Rohr JC; Wagner HJ; Lauten M; Wacker HH; Jüttner E; Hanke C; Pohl M; Niemeyer CM
    Pediatr Transplant; 2008 Jun; 12(4):426-31. PubMed ID: 18466428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease.
    Krishnamurthy S; Hassan A; Frater JL; Paessler ME; Kreisel FH
    Int J Surg Pathol; 2010 Aug; 18(4):278-85. PubMed ID: 19578050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.
    Orjuela M; Gross TG; Cheung YK; Alobeid B; Morris E; Cairo MS
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3945S-52S. PubMed ID: 14506193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.
    Gross TG; Orjuela MA; Perkins SL; Park JR; Lynch JC; Cairo MS; Smith LM; Hayashi RJ
    Am J Transplant; 2012 Nov; 12(11):3069-75. PubMed ID: 22883417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant lymphoproliferative disorders.
    Singavi AK; Harrington AM; Fenske TS
    Cancer Treat Res; 2015; 165():305-27. PubMed ID: 25655616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
    J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.